Inactive Instrument

Press Releases Jaguar Health Inc Nasdaq

Equities

US47008L1061

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society Congress in Support of Company's Expanding Focus on Cancer Supportive Care	Apr. 23	AQ
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care	Apr. 19	AQ
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders	Apr. 10	AQ
Jaguar Health Granted Extension until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement	Apr. 09	AQ
Jaguar Health : Corporate Presentation – April 1, 2024	Apr. 05	PU
Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International	Apr. 03	AQ
Jaguar Health Reports 2023 Financial Results	Apr. 02	AQ
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials and Corporate Updates	Mar. 28	AQ
Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance	Feb. 26	AQ
Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief	Feb. 15	AQ
Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea	Feb. 13	AQ
Magdalena Biosciences, a Joint Venture between Jaguar Health and Filament Health, Study Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical Regions	Jan. 31	AQ
Jaguar Health to Present January 31 at the Microcap Conference and Participate in a Fireside Chat February 1 at the Lytham Partners Investor Select Conference	Jan. 30	AQ
Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health's Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea	Jan. 26	AQ
Jaguar Health : Corporate Presentation – December 11, 2023	Dec. 19	PU
A Majority of Subjects in Jaguar Health s Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage II	Dec. 12	AQ
Jaguar Health - Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals, Published on San Antonio Breast Cancer Symposium Website	Dec. 07	AQ
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs	Dec. 05	AQ
Jaguar Health : Corporate Presentation – December 1, 2023	Dec. 01	PU
Top Line Data for Jaguar Health's Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Forthcoming	Nov. 22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Jaguar Health Inc Nasdaq

Equities

US47008L1061

Press Releases

Filters